Show simple item record

dc.creatorNikolić, Dragana
dc.creatorKatsiki, Niki
dc.creatorMontalto, Giuseppe
dc.creatorIsenović, Esma R.
dc.creatorMikhailidis, Dimitri P.
dc.creatorRizzo, Manfredi
dc.date.accessioned2018-03-01T23:15:33Z
dc.date.available2018-03-01T23:15:33Z
dc.date.issued2013
dc.identifier.issn2072-6643 (print)
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/5380
dc.description.abstractSmall, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in these subjects. Statins are the lipid-lowering drug of choice. Also, anti-obesity and lipid lowering drugs other than statins could be useful in these patients. However, the effects of anti-obesity drugs on CVD risk factors remain unclear. We review the clinical significance of sdLDL in being overweight and obesity, as well as the efficacy of anti-obesity drugs on LDL subfractions in these individuals; a short comment on HDL subclasses is also included. Our literature search was based on PubMed and Scopus listings. Further research is required to fully explore both the significance of sdLDL and the efficacy of anti-obesity drugs on LDL subfractions in being overweight, obesity and MetS. Improving the lipoprotein profile in these patients may represent an efficient approach for reducing cardiovascular risk.en
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173033/RS//
dc.relationGenzyme, Pfizer, Novartis, MSD, Abbott, Astra-Zeneca, Bracco, Bromatech, Chiesi Farmaceutici, Novo-Nordisk, Rikrea, Servier
dc.rightsopenAccessen
dc.sourceNutrientsen
dc.subjectlipoproteinsen
dc.subjectsmall dense low density lipoproteinen
dc.subjectobesityen
dc.subjectmetabolic syndromeen
dc.subjectobesity treatmenten
dc.subjectanti-obesity drugsen
dc.subjectlipid-lowering drugsen
dc.titleLipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approachesen
dc.typereviewen
dcterms.abstractМикхаилидис, Димитри П.; Риззо, Манфреди; Монталто, Гиусеппе; Николић Драгана; Исеновић Есма; Катсики, Ники;
dc.citation.volume5
dc.citation.issue3
dc.citation.spage928
dc.citation.epage948
dc.identifier.wos000316610400019
dc.identifier.doi10.3390/nu5030928
dc.citation.rankM21
dc.identifier.pmid23507795
dc.identifier.scopus2-s2.0-84875303002
dc.identifier.fulltexthttp://vinar.vin.bg.ac.rs//bitstream/id/13345/5376.pdf


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record